Stifel Upgrades Biogen (BIIB) to Buy; 'Lecanemab Skepticism Seems Overdone'
Tweet Send to a Friend
Stifel analyst Paul Matteis upgraded Biogen (NASDAQ: BIIB) from Hold to Buy with a price target of $299.00.The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
